Special Interest Group (SIG)

ADMET Special Interest Group (SIG)

Wednesday, February 7
12:00 PM - 1:15 PM
Location: 17A

The mission of the Absorption, Distribution, Metabolism and Toxicology SIG is to advance drug discovery and development by promoting the discussion and dissemination of principles, topics and ideas for the integration of higher throughput technologies with methods for determining toxicity, pharmacokinetics and metabolism. The goal is to accelerate the drug discovery pipeline and shorten the time of the development of new drugs that cure illnesses and improve quality of life. This special interest group creates a bridge and network between scientists working in the fields of preclinical research, pharmacology, pharmacokinetics and those who are the producers of combinatorial libraries.

The following session will be presented:
Practical Aspects of High-Throughput in vitro ADME

Amy Siu

Scientist
Eisai Inc.

Amy Siu, M.S., Scientist, Eisai Inc.
Amy Siu is currently a Scientist at Eisai Inc. in Andover, MA. She has been the Head of the Drug Metabolism Group since 2012. Prior to this, she was a principal scientist in the DMPK of Infectious Disease CEDD at GlaxoSmithKline Inc. in Research Triangle Park, North Carolina. She received her master’s degree in Nutritional Biochemistry from the University of North Carolina at Chapel. She currently chairs the SLAS ADMET Special Interest Group and participates in the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Working Group for Drug Metabolizing Enzyme Induction. Through her work conducted at GlaxoSmithKline, Amy Siu holds a patent entitled “Methods for detecting LP-PLA2 activity and inhibition of LP-PLA2 activity”. She is a member of the International Society for the Study of Xenobiotics.

Presentation(s):

Send Email for Amy Siu

Ritu Singh

Presentation(s):

Send Email for Ritu Singh

Michael Wester

Research Fellow I
Vertex Pharmaceuticals

For the past 3 years, Michael Wester, PhD, leading the high-throughput in vitro ADME team in his role as Research Fellow I within the DMPK department at Vertex Pharmaceuticals in San Diego. Prior to Vertex, Mike spent 3 years leading the HT in vitro/in silico ADME team at AstraZeneca in Molndal Sweden. In these roles, Mike's teams have been responsible for rapidly providing large quantities of high-quality data to help discovery projects optimize DMPK properties of drug candidates. Prior to joining AstraZeneca, Mike spent 7 years at Pfizer in San Diego where his role stradled DMPK and Structural Biology and he and his team worked to use CYP450 binding mode data to inform drug design for optimal clearance and drug-drug interaction properties. Mike received his PhD in Toxicology from the University of New Mexico College of Pharmacy and subsequently spent 5 years at The Scripps Research Institute. In these academic roles,Mike's research focused on characterizing the enzymology and structure-function relationship of key xenobiotic metabolizing isoforms of the cytochrome P450 family of enzymes.

Presentation(s):

Send Email for Michael Wester


Assets

ADMET Special Interest Group (SIG)



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for ADMET Special Interest Group (SIG)